Summit Therapeutics (SMMT) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChartTranscripts

SMMT Stock Forecast


Summit Therapeutics stock forecast is as follows: an average price target of $36.00 (represents a 80.36% upside from SMMT’s last price of $19.96) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

SMMT Price Target


The average price target for Summit Therapeutics (SMMT) is $36.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $23.00. This represents a potential 80.36% upside from SMMT's last price of $19.96.

SMMT Analyst Ratings


Buy

According to 2 Wall Street analysts, Summit Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SMMT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Summit Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 27, 2024Yigal NochomovitzSummit Redstone Partners$23.00$20.8910.13%15.23%
Sep 25, 2024Brad CaninoStifel Nicolaus$40.00$24.0066.67%100.40%
Sep 16, 2024Mitchell KapoorH.C. Wainwright$45.00$31.9340.93%125.45%
Jun 03, 2024Brad CaninoStifel Nicolaus$14.00$8.6961.20%-29.86%
Mar 25, 2024Brad CaninoStifel Nicolaus$8.00$3.28143.90%-59.92%
Row per page
Go to

The latest Summit Therapeutics stock forecast, released on Sep 27, 2024 by Yigal Nochomovitz from Summit Redstone Partners, set a price target of $23.00, which represents a 10.13% increase from the stock price at the time of the forecast ($20.89), and a 15.23% increase from SMMT last price ($19.96).

Summit Therapeutics Price Target by Period


1M3M12M
# Anlaysts-35
Avg Price Target-$36.00$26.00
Last Closing Price$19.96$19.96$19.96
Upside/Downside-100.00%80.36%30.26%

In the current month, the average price target of Summit Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Summit Therapeutics's last price of $19.96. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Oct 31, 2024H.C. WainwrightBuyBuyHold
Oct 04, 2024H.C. WainwrightBuyBuyHold
Sep 27, 2024CitigroupBuyNeutralDowngrade
Sep 09, 2024CitigroupBuyBuyHold
Sep 03, 2024H.C. WainwrightBuyBuyHold
Aug 12, 2024H.C. Wainwright-BuyInitialise
Jul 19, 2024CitigroupBuyBuyHold
May 31, 2024CitigroupBuyBuyHold
May 07, 2024Citigroup-BuyInitialise
Row per page
Go to

Summit Therapeutics's last stock rating was published by H.C. Wainwright on Oct 31, 2024. The company gave SMMT a "Buy" rating, the same as its previous rate.

Summit Therapeutics Financial Forecast


Summit Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 18Sep 17
Revenue--------$57.00K$192.00K$185.00K$181.00K$170.00K$312.96K----
Avg Forecast-------$9.74M$3.22M$3.19M$2.90M$3.16M$3.21M$4.22M$3.83M$177.69K$5.30M$21.25M
High Forecast-------$9.74M$3.22M$3.19M$2.90M$3.16M$3.21M$4.22M$3.83M$213.23K$6.37M$25.49M
Low Forecast-------$9.74M$3.22M$3.19M$2.90M$3.16M$3.21M$4.22M$3.83M$142.15K$4.24M$17.00M
# Analysts-------171313779814711
Surprise %--------0.02%0.06%0.06%0.06%0.05%0.07%----

Summit Therapeutics's average Quarter revenue forecast for Dec 23 based on 1 analysts is $9.74M, with a low forecast of $9.74M, and a high forecast of $9.74M. SMMT's average Quarter revenue forecast represents a 16990.48% increase compared to the company's last Quarter revenue of $57.00K (Jun 21).

Summit Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 18Sep 17
# Analysts-------171313779814711
EBITDA--------$-23.75M$-17.00M$-13.27M$-17.34M$-14.91M$-6.90M----
Avg Forecast-------$-5.84M$-9.46M$-1.91M$-1.74M$-1.47B$-1.93M$-2.53M$-2.30M$-6.91M$-8.64M$11.09M
High Forecast-------$-5.84M$-7.57M$-1.91M$-1.74M$-1.18B$-1.93M$-2.53M$-2.30M$-5.53M$-6.91M$13.31M
Low Forecast-------$-5.84M$-11.35M$-1.91M$-1.74M$-1.77B$-1.93M$-2.53M$-2.30M$-8.30M$-10.36M$8.87M
Surprise %--------2.51%8.89%7.63%0.01%7.74%2.72%----

undefined analysts predict SMMT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Summit Therapeutics's previous annual EBITDA (undefined) of $NaN.

Summit Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 18Sep 17
# Analysts-------171313779814711
Net Income--------$-25.10M$-18.05M$-13.44M$-17.70M$-15.28M$-6.11M----
Avg Forecast$-51.55M$-45.82M$-45.82M$-45.82M$-43.68M$-36.25M$-34.60M$1.20B$-9.72M$-87.08M$-109.19M$-1.51B$-51.11M$-14.67M$-118.98M$-7.66M$-7.99M$12.24M
High Forecast$-51.55M$-45.82M$-45.82M$-45.82M$-43.68M$-36.25M$-34.60M$1.20B$-7.78M$-87.08M$-109.19M$-1.20B$-51.11M$-14.67M$-118.98M$-6.12M$-6.39M$14.69M
Low Forecast$-51.55M$-45.82M$-45.82M$-45.82M$-49.92M$-36.25M$-34.60M$1.20B$-11.67M$-87.08M$-109.19M$-1.81B$-51.11M$-14.67M$-118.98M$-9.19M$-9.59M$9.79M
Surprise %--------2.58%0.21%0.12%0.01%0.30%0.42%----

Summit Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SMMT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Summit Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 18Sep 17
# Analysts-------171313779814711
SG&A--------$5.98M$4.18M$5.80M$7.46M$5.77M$646.95K----
Avg Forecast-------$173.48M$2.38M$56.78M$51.60M$56.24M$57.15M$75.22M$68.18M$3.16M$3.65M$2.79M
High Forecast-------$173.48M$2.86M$56.78M$51.60M$56.24M$57.15M$75.22M$68.18M$3.80M$4.39M$3.35M
Low Forecast-------$173.48M$1.91M$56.78M$51.60M$56.24M$57.15M$75.22M$68.18M$2.53M$2.92M$2.23M
Surprise %--------2.51%0.07%0.11%0.13%0.10%0.01%----

Summit Therapeutics's average Quarter SG&A projection for Dec 23 is $173.48M, based on 1 Wall Street analysts, with a range of $173.48M to $173.48M. The forecast indicates a 2798.98% rise compared to SMMT last annual SG&A of $5.98M (Jun 21).

Summit Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 23Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 18Sep 17
# Analysts-------171313779814711
EPS--------$-0.28$-0.22$-0.18$-0.26$-0.23$-0.09----
Avg Forecast$-0.07$-0.06$-0.06$-0.06$-0.06$-0.05$-0.05$1.65$-0.13$-0.12$-0.15$-0.19$-0.07$-0.02$-0.17$-0.67$-0.75$0.30
High Forecast$-0.07$-0.06$-0.06$-0.06$-0.06$-0.05$-0.05$1.65$-0.13$-0.12$-0.15$-0.19$-0.07$-0.02$-0.17$-0.54$-0.59$0.36
Low Forecast$-0.07$-0.06$-0.06$-0.06$-0.07$-0.05$-0.05$1.65$-0.13$-0.12$-0.15$-0.19$-0.07$-0.02$-0.17$-0.80$-0.90$0.24
Surprise %--------2.15%1.79%1.17%1.40%3.19%4.38%----

According to undefined Wall Street analysts, Summit Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SMMT previous annual EPS of $NaN (undefined).

Summit Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ELEVElevation Oncology$0.52$9.001630.77%Buy
KRONKronos Bio$0.95$7.63703.16%Buy
NKTXNkarta$3.23$21.60568.73%Buy
KZRKezar Life Sciences$7.09$17.50146.83%Buy
CGEMCullinan Oncology$15.92$31.5097.86%Buy
SMMTSummit Therapeutics$19.96$36.0080.36%Buy
ZURAZura Bio$4.37$5.0014.42%Buy

SMMT Forecast FAQ


Yes, according to 2 Wall Street analysts, Summit Therapeutics (SMMT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of SMMT's total ratings.

Summit Therapeutics (SMMT) average price target is $36 with a range of $23 to $45, implying a 80.36% from its last price of $19.96. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for SMMT stock, the company can go up by 80.36% (from the last price of $19.96 to the average price target of $36), up by 125.45% based on the highest stock price target, and up by 15.23% based on the lowest stock price target.

SMMT's average twelve months analyst stock price target of $36 supports the claim that Summit Therapeutics can reach $30 in the near future.

Summit Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-115M (high $-115M, low $-121M), average SG&A $0 (high $0, low $0), and average EPS is $-0.159 (high $-0.159, low $-0.167). SMMT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-189M (high $-189M, low $-189M), average SG&A $0 (high $0, low $0), and average EPS is $-0.26 (high $-0.26, low $-0.26).

Based on Summit Therapeutics's last annual report (Dec 2020), the company's revenue was $860K, which missed the average analysts forecast of $13.49M by -93.62%. Apple's EBITDA was $-51.475M, missing the average prediction of $-1.481B by -96.52%. The company's net income was $-52.697M, missing the average estimation of $-1.68B by -96.86%. Apple's SG&A was $19.23M, missing the average forecast of $240.21M by -91.99%. Lastly, the company's EPS was $-0.76, beating the average prediction of $-0.433 by 75.49%. In terms of the last quarterly report (Jun 2021), Summit Therapeutics's revenue was $57K, missing the average analysts' forecast of $3.22M by -98.23%. The company's EBITDA was $-23.751M, beating the average prediction of $-9.457M by 151.15%. Summit Therapeutics's net income was $-25.102M, beating the average estimation of $-9.722M by 158.21%. The company's SG&A was $5.98M, beating the average forecast of $2.38M by 151.15%. Lastly, the company's EPS was $-0.28, beating the average prediction of $-0.13 by 114.87%